Invex Therapeutics Ltd (IXC.AX)
AUD 0.06
(0.0%)
AUD 0.06
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 3.34 Million AUD | -62.74% |
| 2023 | 8.97 Million AUD | 111.69% |
| 2022 | 4.24 Million AUD | 73.65% |
| 2021 | 2.44 Million AUD | -28.33% |
| 2020 | 3.4 Million AUD | 1367.37% |
| 2019 | 232.25 Thousand AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 3.34 Million AUD | -62.76% |
| 2024 Q2 | 2.48 Million AUD | 0.0% |
| 2024 Q4 | 856.54 Thousand AUD | 0.0% |
| 2023 Q3 | 2.55 Million AUD | -44.97% |
| 2023 FY | 8.97 Million AUD | 111.69% |
| 2023 Q4 | 4.36 Million AUD | 70.75% |
| 2023 Q2 | 4.64 Million AUD | 138.37% |
| 2023 Q1 | 1.94 Million AUD | -11.34% |
| 2022 Q2 | 2.01 Million AUD | 138.37% |
| 2022 Q1 | 846.76 Thousand AUD | -33.44% |
| 2022 FY | 4.24 Million AUD | 73.65% |
| 2022 Q4 | 2.19 Million AUD | 74.23% |
| 2022 Q3 | 1.26 Million AUD | -37.53% |
| 2021 FY | 2.44 Million AUD | -28.33% |
| 2021 Q1 | 179.21 Thousand AUD | -91.87% |
| 2021 Q4 | 1.27 Million AUD | 100.0% |
| 2021 Q3 | 636.05 Thousand AUD | -45.66% |
| 2021 Q2 | 1.17 Million AUD | 553.19% |
| 2020 FY | 3.4 Million AUD | 1367.37% |
| 2020 Q4 | 2.2 Million AUD | 1130.69% |
| 2020 Q3 | 179.21 Thousand AUD | -85.1% |
| 2020 Q2 | 1.2 Million AUD | 100.0% |
| 2020 Q1 | 601.25 Thousand AUD | 0.0% |
| 2019 Q3 | 11.19 Thousand AUD | 0.0% |
| 2019 FY | 232.25 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -371.107% |
| BTC Health Limited | -1.03 Million AUD | 422.052% |
| CSL Limited | 7.56 Billion AUD | 99.956% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 94.058% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | 89.309% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | 18.895% |
| Orthocell Limited | 15.36 Million AUD | 78.23% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -275.039% |
| Race Oncology Limited | 14.77 Million AUD | 77.347% |
| Starpharma Holdings Limited | 22.81 Million AUD | 85.335% |
| AdAlta Limited | 6.76 Million AUD | 50.574% |
| Zelira Therapeutics Limited | 5.94 Million AUD | 43.753% |
| Memphasys Limited | 3.67 Million AUD | 9.039% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -70.255% |
| Acrux Limited | 8.55 Million AUD | 60.867% |
| Bio-Gene Technology Limited | 2.76 Million AUD | -21.183% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -455.961% |
| Cynata Therapeutics Limited | 11.12 Million AUD | 69.921% |
| Nyrada Inc. | 4.55 Million AUD | 26.548% |
| PharmAust Limited | 6.65 Million AUD | 49.739% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -1018.172% |
| Arovella Therapeutics Limited | 10.78 Million AUD | 68.977% |
| Alterity Therapeutics Limited | 23.4 Million AUD | 85.705% |
| Amplia Therapeutics Limited | 8.43 Million AUD | 60.337% |
| Biome Australia Limited | 7.91 Million AUD | 57.707% |
| Biotron Limited | 5.11 Million AUD | 34.531% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | 83.074% |
| EZZ Life Science Holdings Limited | 39.57 Million AUD | 91.545% |
| Immutep Limited | 42.87 Million AUD | 92.196% |
| Imugene Limited | 135.09 Million AUD | 97.523% |
| Noxopharm Limited | 7 Million AUD | 52.203% |
| Patrys Limited | 4.93 Million AUD | 32.178% |
| Prescient Therapeutics Limited | 10.89 Million AUD | 69.3% |
| PYC Therapeutics Limited | 60.91 Million AUD | 94.507% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 98.757% |
| Dimerix Limited | 25.64 Million AUD | 86.952% |
| Hexima Limited | 1 Million AUD | -231.686% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | 89.767% |
| Nanollose Limited | 12.5 Thousand AUD | -26664.923% |
| Tissue Repair Ltd | 6.66 Million AUD | 49.813% |
| AnteoTech Limited | 12.18 Million AUD | 72.545% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 94.861% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | 84.57% |
| Avecho Biotechnology Limited | 4.54 Million AUD | 26.39% |
| Actinogen Medical Limited | 22.77 Million AUD | 85.306% |
| Immuron Limited | 9.13 Million AUD | 63.385% |
| Argenica Therapeutics Limited | 8.26 Million AUD | 59.538% |